Objective To evaluate the clinical effectiveness, tolerability, and impact on quality of life of Hymovis in the conservative treatment of overuse cartilage lesions due to osteoarthritis and/or meniscus tears. Patients and methods: Non-interventional, prospective, descriptive, observational, multicenter study of 165 patients aged over 18 years with osteoarthritis and/or a meniscus tear treated with two injections of Hymovis. Follow-up visits were held at 10 days and at 1, 2, and 3 months for all patients and at 6 months for patients with osteoarthritis with or without a meniscus tear. Clinical and functional parameters were collected at each participating clinic and patients also completed the Knee Injury and Osteoarthritis Outcome Score (KOOS) and the Western Ontario and McMaster Universities Arthritis Index (WOMAC). Results Patients in all three groups (osteoarthritis, meniscus tear, and osteoarthritis plus meniscus tear) reported a marked and significant reduction in pain after treatment with Hymovis. At 6 months, patients with osteoarthritis and combined lesions showed improvements of the signs and symptoms associated with the pathology. Patients with only OA showed also improvement in palpation, mobility, and joint movement parameters. Patients in the meniscus tear group showed improvements in physical examination, clinical manoeuvre, and joint movement parameters. Additional improvements were observed for quality of life, activities of daily living, and sport and recreation. Satisfaction with treatment was very high, with 85% of osteoarthritis patients reporting considerable or very considerable improvement. None of the patients reported any severe adverse effects. Conclusions Hymovis is a safe and effective option for the conservative treatment of overuse cartilage lesions in the knee due to osteoarthritis and/or meniscus tears.
Background: Knee osteoarthritis (KOA) and meniscal tears (MT) are the two most common types of knee injuries having an important impact on the quality of life of patients (QoL). The objective is to evaluate the impact on the QoL, physical activity and satisfaction degree of patients with KOA, MT or both conditions after intraarticular Hymovis infiltration. Methods: Non-interventional, prospective, multicenter study of 165 patients with KOA and/or a MT treated with two injections of Hymovis. Results: Patients in all three groups (KOA, MT and mixed) reported a high percentage of global QoL improvement (>80 %). KOOS and WOMAC change from baseline improved (p<0.001) for all patients. Physical, sports and recreational activities and Satisfaction with the treatment increased after treatment. (p<0.001). Pain also improved in the three groups (p<0.05). Conclusion: Intra-articular injections of Hymovis improves QoL, physical function and clinical condition of patients suffering KOA, MT or both conditions.
Background: Knee osteoarthritis (KOA) and meniscal tears (MT) are the two most common types of knee injuries having an important impact on the quality of life of patients (QoL). The objective is to evaluate the impact on the QoL, physical activity, and satisfaction degree of patients with KOA, MT, or both conditions after intra-articular Hymovis infiltration. Methods: Non-interventional, prospective, multicenter study of 165 patients with KOA and/or MT treated with two injections of Hymovis. Results: Patients in all three groups (KOA, MT, and mixed) reported a high percentage of global QoL improvement (>80 %). KOOS and WOMAC changes from baseline improved (p<0.001) for all patients. Physical, sports and recreational activities and satisfaction with the treatment increased after treatment. (p<0.001). Pain also improved in the three groups (p<0.05). Conclusion: Intra-articular injection of Hymovis improves QoL, physical function, and clinical condition of patients suffering KOA, MT, or both conditions
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.